Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPITFIRE: Taldefgrobep alfa in ambulatory boys with Duchenne Muscular Dystrophy
NCT03039686Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2017
- Primary completion
- Apr 2020
- Countries
- 13
01
Overview
A Phase 3 trial of taldefgrobep alfa in Duchenne muscular dystrophy (DMD), sponsored by Roche. Started Jul 2017; status: completed.
02
Drugs
taldefgrobep alfa
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03039686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03039686.